Radiomics predicts survival of patients with advanced non-small cell lung cancer undergoing PD-1 blockade using Nivolumab

Immune checkpoint blockade is an emerging anticancer strategy, and Nivolumab is a human mAb to PD-1 that is used in the treatment of a number of different malignancies, including non-small cell lung cancer (NSCLC), kidney cancer, urothelial carcinoma and melanoma. Although the use of Nivolumab prolo...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncol Lett
Auteurs principaux: Nardone, Valerio, Tini, Paolo, Pastina, Pierpaolo, Botta, Cirino, Reginelli, Alfonso, Carbone, Salvatore Francesco, Giannicola, Rocco, Calabrese, Grazia, Tebala, Carmela, Guida, Cesare, Giudice, Aldo, Barbieri, Vito, Tassone, Pierfrancesco, Tagliaferri, Pierosandro, Cappabianca, Salvatore, Capasso, Rosanna, Luce, Amalia, Caraglia, Michele, Mazzei, Maria Antonietta, Pirtoli, Luigi, Correale, Pierpaolo
Format: Artigo
Langue:Inglês
Publié: D.A. Spandidos 2020
Sujets:
Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6956423/
https://ncbi.nlm.nih.gov/pubmed/31966081
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2019.11220
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires